VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

MDS 2020 | ASO tominersen for Huntington’s disease in Phase III trials

Edward Wild • 4 Sep 2020
MDS 2020
Huntington’s Disease Movement Disorders Tominersen
Treatment Trial Updates

Edward Wild, MA, MB BChir, FRCP, PhD, UCL Queen Square Institute of Neurology, London, UK, discusses the root cause of Huntington’s disease via the protein huntingtin and how antisense oligonucleotides (ASOs) can target it. Tominersen, previously called RG6042, shows potential and is currently in Phase III efficacy clinical trials (NCT03761849). This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Edward Wild

4:52
Endo-lysosomal pathway proteins as potential Huntington’s disease biomarkers
Edward Wild • 4 Sep 2020
4:47
Somatic instability in Huntington’s disease and potential treatments
Edward Wild • 4 Sep 2020
2:42
Molecular therapeutic development for neurodegenerative disorders
Edward Wild • 4 Sep 2020

Related Videos

2:44
Biological subtyping: the future of neurodegenerative diseases
Alberto Espay • 27 Apr 2023
2:29
Rethinking anti-protein therapies for neurodegenerative diseases
Alberto Espay • 27 Apr 2023
3:31
ND0612 vs oral immediate-release levodopa/carbidopa in patients with PD and motor fluctuations
Alberto Espay • 27 Apr 2023
3:02
Improvements to levodopa-based treatments for Parkinson’s disease
Alberto Espay • 27 Apr 2023
The content of VJNeurology is intended for healthcare professionals